# Phase 2 Precursor Cell: 73 recruiting (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 73 trials in phase 2 for Precursor Cell Lymphoblastic Leukemia-Lymphoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma trials: 73 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/precursor-cell-lymphoblastic-leukemia-lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 73
- Recruiting or not yet: 73
- Read on: November 19, 2026

## Trials

The 25 newest of 73, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07940621 | Inotuzumab Plus Venetoclax in Older or Unfit Patients With Newly Diagnosed BCR::ABL1-Negative B-ALL | Ruijin Hospital | Phase 2 | Not yet recruiting | Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell... | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940621) |
| September 14, 2026 | NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic... | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute... | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819396) |
| May 8, 2026 | NCT07575412 | SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS | The First Affiliated Hospital of Soochow University | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell, Conditioning Therapy, SHR2554... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575412) |
| May 5, 2026 | NCT07566377 | Cord Blood Transplantation in Children and Young Adults With Blood Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin... | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566377) |
| May 1, 2026 | NCT07562568 | SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS | The First Affiliated Hospital of Soochow University | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell, Conditioning Therapy, SHR2554... | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07562568) |
| February 10, 2026 | NCT07400029 | A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07400029) |
| January 9, 2026 | NCT07328503 | CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, B-All | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328503) |
| December 24, 2025 | NCT07301424 | Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL | University of Alberta | Phase 2 | Not yet recruiting | Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301424) |
| December 24, 2025 | NCT07301138 | BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients | Ruijin Hospital | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301138) |
| November 14, 2025 | NCT07228741 | Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity | St. Jude Children's Research Hospital | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Obesity | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07228741) |
| November 12, 2025 | NCT07227584 | ALL Backbone in AYAs | Dana-Farber Cancer Institute | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia... | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227584) |
| November 4, 2025 | NCT07224100 | Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute... | University of Washington | Phase 2 | Recruiting | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With... | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07224100) |
| September 17, 2025 | NCT07178912 | Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive... | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Phase II Clinical Trial, Blinatumomab, Olverembatinib, Lymphoblastic Leukemia, Philadelphia Chromosome Positive | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07178912) |
| July 8, 2025 | NCT07053059 | Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Acute Lymphocytic Leukemia (ALL) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07053059) |
| May 22, 2025 | NCT06985485 | Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy | The First Affiliated Hospital of Soochow University | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab, Inotuzumab Ozogamicin | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06985485) |
| April 16, 2025 | NCT06930105 | Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Acute Lymphoid Leukemia (ALL) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06930105) |
| April 9, 2025 | NCT06918431 | Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia... | City of Hope Medical Center | Phase 2 | Recruiting | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06918431) |
| April 1, 2025 | NCT06904482 | Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood | Case Comprehensive Cancer Center | Phase 2 | Recruiting | aGVHD, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06904482) |
| March 20, 2025 | NCT06886074 | Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Measurable Residual Disease (MRD) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06886074) |
| March 6, 2025 | NCT06861348 | Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT | First Affiliated Hospital of Zhejiang University | Phase 2 | Not yet recruiting | Leukemia, Lymphocytic, Acute | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06861348) |
| March 5, 2025 | NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With... | Center for International Blood and Marrow Transplant Research | Phase 2 | Recruiting | AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic... | 358 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859424) |
| February 26, 2025 | NCT06847269 | CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia | St. Jude Children's Research Hospital | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06847269) |
| February 10, 2025 | NCT06816134 | Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia | The First Affiliated Hospital of Soochow University | Phase 2 | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell, Conditioning Therapy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06816134) |
| February 7, 2025 | NCT06815003 | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients... | City of Hope Medical Center | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease... | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06815003) |
| January 15, 2025 | NCT06777264 | Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1 | First Affiliated Hospital of Zhejiang University | Phase 2 | Not yet recruiting | Acute Lymphoblastic Leukemia, B Cell ALL | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06777264) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 5 |
| First Affiliated Hospital of Zhejiang University | 5 |
| The First Affiliated Hospital of Soochow University | 4 |
| Masonic Cancer Center, University of Minnesota | 4 |
| City of Hope Medical Center | 4 |
| Fred Hutchinson Cancer Center | 4 |
| The First Affiliated Hospital of Zhengzhou University | 4 |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| Ruijin Hospital | 3 |
| St. Jude Children's Research Hospital | 3 |
| Memorial Sloan Kettering Cancer Center | 2 |
| Northside Hospital, Inc. | 2 |
| Juventas Cell Therapy Ltd. | 1 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 1 |
| KK Women's and Children's Hospital | 1 |
| Charite University, Berlin, Germany | 1 |
| National Cancer Institute (NCI) | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| Case Comprehensive Cancer Center | 1 |
| University of Birmingham | 1 |
| Center for International Blood and Marrow Transplant Research | 1 |
| University of Alberta | 1 |
| Imperial College London | 1 |
| University of Chicago | 1 |
| Instituto do Cancer do Estado de São Paulo | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 36 |
| China | 22 |
| United Kingdom | 3 |
| South Korea | 3 |
| Australia | 2 |
| Austria | 2 |
| Belgium | 2 |
| Czechia | 2 |
| Denmark | 2 |
| Finland | 2 |
| France | 2 |
| Israel | 2 |
| Italy | 2 |
| Netherlands | 2 |
| Norway | 2 |
| Sweden | 2 |
| Singapore | 1 |
| Poland | 1 |
| Portugal | 1 |
| Canada | 1 |
| Brazil | 1 |
| Mexico | 1 |
| Germany | 1 |
| Slovakia | 1 |
| Spain | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Metal fabricators in the United States](https://specstream.ai/data/businesses/metal-fabricators/united-states)
- [Assisted living facilities in the United States](https://specstream.ai/data/businesses/assisted-living-facilities/united-states)
- [Immunodermatology practices in the United States](https://specstream.ai/data/businesses/immunodermatology-practices/united-states)
- [Trucking companies in the United States](https://specstream.ai/data/businesses/trucking-companies/united-states)
- [Ferry boat companies in the United States](https://specstream.ai/data/businesses/ferry-boat-companies/united-states)
- [Scandinavian restaurants in the United States](https://specstream.ai/data/businesses/scandinavian-restaurants/united-states)
